• Tuberculosis and Respiratory Diseases
• /
• v.79 no.2
• /
• pp.70-73
• /
• 2016

In late March of 2009, an outbreak of influenza in Mexico, was eventually identified as H1N1 influenza A. In June 2009, the World Health Organization raised a pandemic alert to the highest level. More than 214 countries have reported confirmed cases of pandemic H1N1 influenza A. In Korea, the first case of pandemic influenza A/H1N1 infection was reported on May 2, 2009. Between May 2009 and August 2010, 750,000 cases of pandemic influenza A/H1N1 were confirmed by laboratory test. The H1N1-related death toll was estimated to reach 252 individuals. Almost one billion cases of influenza occurs globally every year, resulting in 300,000 to 500,000 deaths. Influenza vaccination induces virus-neutralizing antibodies, mainly against hemagglutinin, which provide protection from invading virus. New quadrivalent inactivated influenza vaccine generates similar immune responses against the three influenza strains contained in two types of trivalent vaccines and superior responses against the additional B strain.

• Korean Journal of Clinical Laboratory Science
• /
• v.42 no.1
• /
• pp.1-15
• /
• 2010

Swine influenza virus (SIV) or swine-origin influenza virus (S-OIV) is endemic in swine, and classified into influenza A and influenza C but not influenza B. Swine influenza A includes H1N1, H1N2, H3N1, H3N2 and H2N3 subtypes. Infection of SIV occurs in only swine and that of S-OIV is rare in human. What human can be infected with S-OIV is called as zoonotic swine flu. Pandemic 2009 swine influenza H1N1 virus (2009 H1N1) was emerged in Mexico, America and Canada and spread worldwide. The triple-reassortant H1N1 resulting from antigenic drift was contained with HA, NA and PB1 of human or swine influenza virus, PB2 and PA polymerase of avian influenza virus, and M, NP and NS of swine influenza virus, The 2009 H1N1 enables to transmit to human and swine. The symptoms and signs in human infected with 2009 H1N1 virus are fever, cough and sore throat, pneumonia as well as diarrhea and vomiting. Co-infection with other viruses and bacteria such as Streptococcus pneumoniae can occur high mortality in high-risk population. 2009 H1N1 virus was easily differentiated from seasonal flu by real time RT-PCR which contributed rapid and confirmed diagnosis. The 2009 H1N1 virus was treated with NA inhibitors such as oseltamivir (Tamiflu) and zanamivir (Relenza) but not with adamantanes such as amantadine and rimantadine. Evolution of influenza virus has continued in various hosts. Development of a more effective vaccine against influenza prototypes is needed to protect new influenza infection such as H5 and H7 subtypes to infect to multi-organ and cause high pathogenicity.

• Tuberculosis and Respiratory Diseases
• /
• v.70 no.4
• /
• pp.285-292
• /
• 2011

After an outbreak of H1N1 influenza A virus infection in Mexico in late March 2009, the World Health Organization raised its pandemic alert level to phase 6, and to the highest level in June 2009. The pandemic H1N1/A influenza was caused by an H1N1 influenza A virus that represents a quadruple reassortment of two swine strains, one human strain, and one avian strain of influenza. After the first case report of H1N1/A infection in early May 2009, South Korea was overwhelmed by this new kind of influenza H1N1/A pandemic, which resulted in a total of 700,000 formally reported cases and 252 deaths. In this article, clinical characteristics of victims of H1N1/A influenza infection, especially those who developed pneumonia and those who were cared for in the intensive care unit, are described. In addition, guidelines for the treatment of H1N1/A influenza virus infection victims in the ICU, which was suggested by the Korean Society of Critical Care Medicine, are introduced.

• Clinical and Experimental Pediatrics
• /
• v.52 no.8
• /
• pp.862-868
• /
• 2009

Since its identification in April 2009, a swine-origin H1N1 influenza A virus (S-OIV) which is a reassortment of gene segments from both North American triple-reassortant and Eurasian swine influenza has been widely spread among humans in unexpected rapidity. To date, each gene segment of the 2009 influenza A (H1N1) outbreak viruses have shown high (99.9%) neucleotide sequence identity. As of July 6, 94,512 people have been infected in 122 countries, of whom 429 have died with an overall case-fatality rate of <0.5%. Most confirmed cases of S-OIV infection have been characterized by self-limited, uncomplicated febrile respiratory illness and 38% of cases have also included vomiting or diarrhea. Standard plus droplet precautions should be adhered to at all times. Tests on S-OIV have indicated that current new H1N1 viruses are sensitive to neuraminidase inhibitors (oseltamivir). However, current less virulent S-OIV may evolve into a pathogenic strain or acquire antiviral resistance, potentially with more severe clinical consequences. Efforts to control these outbreaks would be based on our understanding of novel S-OIV and previous influenza pandemics.

• Nonlinear Functional Analysis and Applications
• /
• v.29 no.2
• /
• pp.597-620
• /
• 2024

In this study, the conformable fractional derivative(CFD) of order 𝝔 in conjunction with the LC operator of orderρ is used to develop the model of the transmission of the A(H1N1) influenza infection. A brand-new A(H1N1) influenza infection model is presented, with a population split into four different compartments. Fixed point theorems were used to prove the existence of the solutions and uniqueness of this model. The basic reproduction number R₀ was determined. The least and most sensitive variables that could alter R₀ were then determined using normalized forward sensitivity indices. Through numerical simulations carried out with the aid of the Adams-Moulton approach, the study also investigated the effects of numerous biological characteristics on the system. The findings demonstrated that if 𝝔 < 1 and ρ < 1 under the CFD, also the findings demonstrated that if 𝝔 = 1 and ρ = 1 under the CFD, the A(H1N1) influenza infection will not vanish.

• Journal of Life Science
• /
• v.33 no.8
• /
• pp.605-611
• /
• 2023

Recently, sporadic cases of human infection by genetic reassortants of H7Nx influenza A viruses have been reported; such viruses have also been continuously isolated from avian species. In this study, A/wild bird/South Korea/sw-anu/2023, a novel reassortant of the H7N1 avian influenza virus, was analyzed using full-genome sequencing and molecular characterization. Phylogenetic analysis showed that A/wild bird/South Korea/sw-anu/2023 belonged to the Eurasian lineage of H7Nx viruses. The polymerase basic (PB)2, PB1, polymerase acidic (PA), and nucleoprotein (NP) genes of these viruses were found to be closely related to those of avian influenza viruses isolated from wild birds, while the hemagglutinin (HA), neuraminidase (NA), matrix (M), and nonstructural (NS) genes were similar to those of avian influenza viruses isolated from domestic ducks. In addition, A/wild bird/South Korea/sw-anu/2023 also had a high binding preference for avian-specific glycans in the solid-phase direct binding assay. These results suggest the presence of a new generation of H7N1 avian influenza viruses in wild birds and highlight the reassortment of avian influenza viruses found along the East Asian-Australasian flyway. Overall, H7Nx viruses circulate worldwide, and mutated H7N1 avian viruses may infect humans, which emphasizes the requirement for continued surveillance of the H7N1 avian influenza virus in wild birds and poultry.

• IMMUNE NETWORK
• /
• v.16 no.5
• /
• pp.311-315
• /
• 2016

A pandemic influenza A (H1N1) virus strain was isolated from a pig farm in Korea in December 2009. The strain was propagated in and isolated from both the Madin-Darby canine kidney cell line and embryonated eggs. The partial and complete sequences of the strain were identical to those of A/California/04/2009, with >99% sequence similarity in the HA, NA, M, NS, NP, PA, PB1, and PB2 genes. The isolated strain was inactivated and used to prepare a swine influenza vaccine. This trial vaccine, containing the new isolate that has high sequence similarity with the pandemic influenza A (H1N1) virus, resulted in seroconversion in Guinea pigs and piglets. This strain could therefore be a potential vaccine candidate for swine influenza control in commercial farms.

• Journal of Microbiology and Biotechnology
• /
• v.28 no.5
• /
• pp.809-815
• /
• 2018

Influenza, which is a highly contagious disease caused by the influenza A virus, continues to be a major health concern worldwide. Although the accurate and early diagnosis of influenza virus infection is important for controlling the spread of this disease and rapidly initiating antiviral therapy, the current influenza diagnostic kits are limited by their low sensitivity. In this study, we developed several new influenza nucleoprotein (NP)-specific monoclonal antibodies (mAbs) and compared their sensitivity and specificity of those with commercially available anti-NP mAbs. Three mAbs, designated M24.11, M34.3, and M34.33, exhibited higher reactivities to recombinant NPs and A/Puerto Rico/8/1934 (H1N1) viral lysates compared with the commercial mAbs, as assessed using enzyme-linked immunosorbent assays. M34.3 and M34.33 showed higher reactivities with A/California/04/09 (pandemic H1N1) and A/Philippines/2/82 (H3N2) viral lysates than the commercial mAbs. In contrast, M24.11 had marked reactivity with H3N2 but not with pandemic H1N1. Immunofluorescent confocal microscopy showed that the three mAbs effectively detected the presence of influenza virus in lung tissues of mice infected with A/Puerto Rico/8/1934. These results indicate that the newly developed M34.3 and M34.33 mAbs could be useful for the development of influenza diagnostics.

• Journal of Microbiology and Biotechnology
• /
• v.21 no.5
• /
• pp.449-454
• /
• 2011

The infection of pandemic influenza viruses such as swine flu (H1N1) and avian flu viruses to the host cells is related to the following two factors: First, the surface protein such as HA (hemagglutinin) and NA (neuraminidase) of the influenza virus. Second, the specific structure of the oligosaccharide [sialic acid(${\alpha}2$-6) galactose(${\beta}1$-4)glucose or sialic acid(${\alpha}2$-3)galactose(${\beta}1$-4)glucose] on the host cell. After recognizing the specific structure of the oligosaccharide on the surface of host cells by the surface protein of the influenza virus, the influenza virus can secrete sialidase and cleave the sialic acid attached on the final position of the specific structure of the oligosaccharide on the surface of host cells. Tamiflu (oseltamivir), known as a remedy of swine flu, has a saccharide analog structure, especially the sialic acid analog. Tamiflu can inhibit the invasion of influenza viruses (swine flu and avian flu viruses) into the host cells by competition with sialic acid on the terminal position of the specific oligosaccharide on the surface of the host cell. Because of the emergence of Tamiflu resistance, the development of new potent anti-influenza inhibitors is needed. The inhibitors with positive-charge groups have potential as antiviral therapeutics, and the strain specificity must also be resolved.

• Journal of the Korean Professional Engineers Association
• /
• v.42 no.6
• /
• pp.42-46
• /
• 2009

Every year influenza contributes to the death of 72 people in the South korea, 20,000 in the U.S. and perhaps millions worldwide. The swine fever so-called the noble flu A H1N1, a strain of the flu virus, which jumped species and burst into the human population in March and April of this year. The outbreak of 2009 novel H1N1 was the fourth in 100 years. Fortunately, it led to today's comparatively tame swine flu than the vicious 1918, which was original H1N1 pandemic flu virus, killed at least 40 million worldwide in an ongoing pandemic era. Although the 2009 H1N1 which is still in full swing, this global flu epidemic is already teaching scientists valuable lessons about pandemics. Evidence accumulated these days indicates that the 2009 H1N1 was not entirely new to all human immune systems. This article introduces only an outline for our better understanding the basic mechanisms of influenza and the vaccination about longstanding fears of that worst-case scenario engendered pandemic that are paying off today.